Patrick T. Lewis

Array ( [id] => 18672959 [patent_doc_number] => 20230310414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS WITH DOUBLE AND TRIPLE COMBINATIONS OF ANTIVIRAL AND IMMUNE MODULATING COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/026568 [patent_app_country] => US [patent_app_date] => 2021-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11403 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -79 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18026568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17385580 [patent_doc_number] => 20220033432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => ANTI-HEPATITIS B VIRUS AGENT [patent_app_type] => utility [patent_app_number] => 17/473635 [patent_app_country] => US [patent_app_date] => 2021-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6321 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17473635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312815 [patent_doc_number] => 20210401863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => TREATMENT AND PREVENTION OF NEISSERIA GONORRHOEAE INFECTION USING CMP-ACTIVATED NONULOSONATE ANALOG COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/447344 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 333 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17447344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17473960 [patent_doc_number] => 20220081464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => Cyclic Di-Nucleotide Induction of Type I Interferon [patent_app_type] => utility [patent_app_number] => 17/464494 [patent_app_country] => US [patent_app_date] => 2021-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17464494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18581647 [patent_doc_number] => 20230263900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => DENDRIMER-DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 18/023029 [patent_app_country] => US [patent_app_date] => 2021-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41603 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18023029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19397108 [patent_doc_number] => 12071450 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-27 [patent_title] => Salts of conjugates for cancer therapy [patent_app_type] => utility [patent_app_number] => 17/460335 [patent_app_country] => US [patent_app_date] => 2021-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 22805 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17460335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17290929 [patent_doc_number] => 20210386768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => COMBINATION MEDICINE [patent_app_type] => utility [patent_app_number] => 17/459412 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17459412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971894 [patent_doc_number] => 20240051986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER [patent_app_type] => utility [patent_app_number] => 18/246393 [patent_app_country] => US [patent_app_date] => 2021-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18803 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 595 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18749403 [patent_doc_number] => 11808708 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-07 [patent_title] => Method for maintaining the health of a diabetic patient by preventing the occurrence of diabetic ketoacidosis [patent_app_type] => utility [patent_app_number] => 17/395916 [patent_app_country] => US [patent_app_date] => 2021-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3782 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17395916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18690958 [patent_doc_number] => 20230321131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT AND PREVENTION OF AN ANTINEOPLASTIC-INDUCED TOXICITY [patent_app_type] => utility [patent_app_number] => 18/040182 [patent_app_country] => US [patent_app_date] => 2021-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19360824 [patent_doc_number] => 20240262858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => SCALABLE PRODUCTION OF POLYRIBONUCLEOTIDES OF CONTROLLED SIZE [patent_app_type] => utility [patent_app_number] => 17/803950 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4424 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17803950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17532553 [patent_doc_number] => 20220111162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => APPARATUS, SYSTEM, AND METHOD FOR FACILITATING INTRANASAL TREATMENT OF A PATIENT [patent_app_type] => utility [patent_app_number] => 17/389152 [patent_app_country] => US [patent_app_date] => 2021-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3044 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17389152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198610 [patent_doc_number] => 20210338704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => CYTARABINE CONJUGATES FOR CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 17/372740 [patent_app_country] => US [patent_app_date] => 2021-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12371 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17372740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537477 [patent_doc_number] => 20230242570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER [patent_app_type] => utility [patent_app_number] => 18/003630 [patent_app_country] => US [patent_app_date] => 2021-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10603 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537477 [patent_doc_number] => 20230242570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER [patent_app_type] => utility [patent_app_number] => 18/003630 [patent_app_country] => US [patent_app_date] => 2021-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10603 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537477 [patent_doc_number] => 20230242570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER [patent_app_type] => utility [patent_app_number] => 18/003630 [patent_app_country] => US [patent_app_date] => 2021-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10603 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548098 [patent_doc_number] => 20220119439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => 5'-Cyclo-Phosphonate Modified Nucleotides [patent_app_type] => utility [patent_app_number] => 17/363983 [patent_app_country] => US [patent_app_date] => 2021-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17363983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18509949 [patent_doc_number] => 20230226041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/001859 [patent_app_country] => US [patent_app_date] => 2021-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001859 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18509949 [patent_doc_number] => 20230226041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/001859 [patent_app_country] => US [patent_app_date] => 2021-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001859 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383829 [patent_doc_number] => 20220031681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones [patent_app_type] => utility [patent_app_number] => 17/346994 [patent_app_country] => US [patent_app_date] => 2021-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17346994 [rel_patent_id] =>[rel_patent_doc_number] =>)